Skip to main content
Clinical Trials/ACTRN12621000889853
ACTRN12621000889853Active, not recruiting未知

Effect on glycaemic outcomes in people with type 2 diabetes initiating continuous glucose monitoring: The 2GO-CGM study

niversity of Otago0 sites71 target enrollmentStarted: July 8, 2021Last updated:

Trial Snapshot

Phase
未知
Status
Active, not recruiting
Enrollment
71

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional
Allocation
Randomised controlled trial
Primary Purpose
Treatment
Masking
Open (masking not used)

Eligibility Criteria

Ages
16 Years to o limit (—)
Sex
All

Inclusion Criteria

  • 1.Type 2 diabetes as per ADA classification
  • 2.HbA1c greater than 8.0%
  • 3.Minimum daily insulin requirement of greater than or equal to 0.2 units insulin/kg/day, for at least 3 months previous to study enrollment.
  • 4.Aged 16 years and over.
  • 5.Be willing and able to conform to the study protocol

Exclusion Criteria

  • 1.History of Type 1 diabetes
  • 2.History of other types of diabetes such as MODY, secondary pancreatic diabetes, diabetes due to endocrinopathies
  • 3.Has had a hospital admission for hyperglycaemia in last 6 months
  • 4.Use of systemic corticosteroids for more than 14 days, or repeated pharmacologic systemic courses of corticosteroids
  • 5.Recurrent or chronic systemic infections that in the view of the investigator would significantly impact on glycaemia.
  • 6.Major cardiovascular event (including or not limited to MI, CVA, CABG, PTCA) or major surgery in last 3 months
  • 7.Active malignancy requiring ongoing treatment
  • 8.Previous or planned bariatric surgery.
  • 9.Pregnancy
  • 10.Any other reason that investigator feels may not be in best interest of patient to participate.

Investigators

Similar Trials

Glycaemic outcomes in people with type 2... | Clinical Trial